MAIA 8-K: SEC filing

MAIA Biotechnology

Filed with the SEC on · accession 0001493152-26-052720

MAIA filed a 8-K (current report) with the SEC on Nov 17, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Summary of the filing

MAIA Biotechnology issued a press release reporting consistent strong efficacy results from its expanded Phase 2 THIO-101 study in non-small cell lung cancer.

Key details

RegistrantMAIA Biotechnology, Inc.
Chief executive officerVlad Vitoc

✦ Ask GOAX AI about this filing — what it means for MAIA, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for MAIA?

Click here

Frequently asked questions

What did MAIA file with the SEC on Nov 17, 2026?

MAIA filed a 8-K (SEC filing). MAIA Biotechnology issued a press release reporting consistent strong efficacy results from its expanded Phase 2 THIO-101 study in non-small cell lung cancer.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Other MAIA SEC filings

Get alerts when MAIA files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days